IQVIA Announces Opening of New Q² Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the opening of a state-of-the-art, 160,000-square-foot lab facility for its Q² Solutions subsidiary. These custom-designed laboratory spaces will be known as Q² Solutions Innovation Laboratories and are located on the new IQVIA Innovation Park Campus in the heart of the dynamic Research Triangle Park in North Carolina. Through a collaboration with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, IQVIA anticipates that this new facility will create up to 750 new jobs in North Carolina over the next 10 years.

The new facility has an innovative suite of laboratory capabilities, including cutting edge bioanalytical, vaccine, biomarker and genomics laboratories. The site is also home to a new Translational Science and Innovation Laboratory (TSAIL). TSAIL will allow customers to access a broad range of services including a cross-disciplined approach to early-stage Research & Development and exploratory human biomarker activities. This will enable biopharmaceutical companies to accelerate drug development.

“The new Innovation Laboratories will provide a state-of-the-art solution to the industry with multiple laboratory disciplines under one roof for biomarker development and delivery,” said Richard Staub, president, R&D Solutions, IQVIA. “The growing need for advanced laboratory capabilities spanning biomarker discovery through next generation vaccine, genomic, and bioanalytical sciences requires the laboratory industry to adapt. Our Innovation Laboratories are designed to fast track the drug development process and provide the agility and range of laboratory sciences under one roof that the industry requires.”

To support this growth and continued expansion, Q² Solutions has begun recruiting for a range of new positions, including many specialized scientific and operational roles, uniting scientific thought leaders from anatomic pathology, flow cytometry, genomics, vaccine development, and bioanalytical services under one roof.

If you are interested in learning more about how you can turn hope into help, please visit the Q2 Solutions careers page to find the next role in your career journey.

About Q² Solutions
Q² Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular and companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q² Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need. To learn more, visit www.q2labsolutions.com.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 74,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005040/en/

Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)

+1.973.316.3828

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)

+1.484.567.6732

Source: IQVIA